Sickle Cell Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain, and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion, and stem cell transplant.
The Sickle Cell Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects.
Sickle Cell Disease Pipeline Drugs Market Segmentation by Targets
Some of the targets in the Sickle Cell Disease pipeline are Hemoglobin Subunit Beta, B Cell Lymphoma/Leukemia 11A, Histone Deacetylase, Hemoglobin, and P Selectin among others. Hemoglobin Subunit Beta was the largest target in the pipeline.
Sickle Cell Disease Pipeline Drugs Market Analysis, by Targets
For more Sickle Cell Disease pipeline drugs market target insights, download a free report sample
Sickle Cell Disease Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the mechanisms of action in the Sickle Cell Disease pipeline drugs market are Hemoglobin Subunit Beta Activator, Histone Deacetylase Inhibitor, B Cell Lymphoma/Leukemia 11A Inhibitor, P Selectin Inhibitor, and Pyruvate Kinase PKLR Activator among others. Hemoglobin Subunit Beta Activator was the leading MoA in the pipeline.
Sickle Cell Disease Pipeline Drugs Market Analysis, by Mechanisms of Action
For more MoA insights into the Sickle Cell Disease pipeline drugs market, download a free report sample
Sickle Cell Disease Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Sickle Cell Disease pipeline drugs market are intravenous, oral, subcutaneous, topical, and parenteral among others. The majority of the pipeline drugs followed the oral route of administration.
Sickle Cell Disease Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Sickle Cell Disease pipeline drugs market, download a free report sample
Sickle Cell Disease Pipeline Drugs Market Segmentation by Molecule Types
The leading molecule types in the Sickle Cell Disease pipeline drugs market are small molecule, gene-modified cell therapy, gene therapy, cell therapy, and monoclonal antibody among others. Small molecule was the leading molecule type in the pipeline.
Sickle Cell Disease Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Sickle Cell Disease pipeline drugs market, download a free report sample
Sickle Cell Disease Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Sickle Cell pipeline drugs market are Beam Therapeutics Inc, Agios Pharmaceuticals Inc, CRISPR Therapeutics AG, Editas Medicine Inc, Global Blood Therapeutics Inc, and Novartis AG. Among these, Global Blood Therapeutics Inc had the most number of products under development in 2022.
Sickle Cell Disease Pipeline Drugs Market Analysis by Key Companies
To know more about the Sickle Cell Disease pipeline drugs market companies, download a free report sample
Sickle Cell Disease Pipeline Drugs Market Report Overview
| Key Targets | Hemoglobin Subunit Beta, B Cell Lymphoma/Leukemia 11A, Histone Deacetylase, Hemoglobin, and P Selectin |
| Key Mechanism of Actions | Hemoglobin Subunit Beta Activator, Histone Deacetylase Inhibitor, B Cell Lymphoma/Leukemia 11A Inhibitor, P Selectin Inhibitor, and Pyruvate Kinase PKLR Activator |
| Key Routes of Administration | Intravenous, Oral, Subcutaneous, Topical, and Parenteral |
| Key Molecule Types | Small Molecule, Gene-Modified Cell Therapy, Gene Therapy, Cell Therapy, and Monoclonal Antibody |
| Key Companies | Beam Therapeutics Inc, Agios Pharmaceuticals Inc, CRISPR Therapeutics AG, Editas Medicine Inc, Global Blood Therapeutics Inc, and Novartis AG |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Some of the key targets of the Sickle Cell Disease pipeline drugs market are Hemoglobin Subunit Beta, B Cell Lymphoma/Leukemia 11A, Histone Deacetylase, Hemoglobin, and P Selectin.
Some of the key mechanisms of action in the Sickle Cell Disease pipeline drugs market are Hemoglobin Subunit Beta Activator, Histone Deacetylase Inhibitor, B Cell Lymphoma/Leukemia 11A Inhibitor, P Selectin Inhibitor, and Pyruvate Kinase PKLR Activator.
The key routes of administration in the Sickle Cell Disease pipeline drugs market are intravenous, oral, subcutaneous, topical, and parenteral.
The molecule types in the Sickle Cell Disease pipeline drugs market are small molecule, monoclonal antibody, peptide, and recombinant protein.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Hematological Disorders reports